Trump Administration Grants 90-Day Delay on Rule Restricting Imported Medicines

Key facts

The decision to pause the implementation of the new pharmaceutical regulation represents a notable tactical shift in federal oversight of cross-border prescription drug acquisition. According to reporting by Ed Silverman, the administration chose to institute a 90-day delay on the rule, which was positioned to tighten restrictions on how individuals in the United States acquire prescription medicines from foreign pharmacies.

The pending regulation aimed to establish stricter oversight and potential prohibitions on international personal importation pathways. Had the rule taken effect immediately as scheduled, it would have empowered federal customs and public health inspectors to step up package interceptions and prohibit overseas vendors from shipping maintenance drugs directly to American residential addresses.

The administrative delay was executed through standard executive rulemaking procedures, which allow executive branch agencies to freeze impending regulations to conduct additional regulatory impact analyses, gather stakeholder feedback, or realign policy goals with broad presidential directives. During this 90-day pause, existing federal guidelines and border enforcement policies will remain unchanged. American consumers will retain their current level of access to international pharmacy orders while regulatory personnel, healthcare advocates, and pharmaceutical industry representatives analyze the potential repercussions of finalizing the restrictive measures.

Why it matters

The 90-day regulatory pause carries immediate financial and clinical consequences for millions of American households, as well as broader implications for the national prescription drug market. Prescription drug expenditure in the United States significantly exceeds per capita spending in other industrialized countries, driven largely by free-market pricing structures, complex intermediary supply chains involving pharmacy benefit managers (PBMs), and delayed generic competition. For uninsured, underinsured, or fixed-income patients managing chronic conditions such as hypertension, diabetes, asthma, and hyperlipidemia, purchasing brand-name medications from regulated Canadian or European pharmacies often provides savings ranging from 30 percent to 80 percent compared to domestic retail list prices.

A sudden restriction on international medicine imports would force many patients to choose between paying full domestic out-of-pocket prices, skipping doses, or abandoning prescribed therapies entirely. Clinical research consistently demonstrates that increased cost-sharing and higher drug prices correlate with non-adherence to therapy, leading to elevated rates of avoidable emergency room visits, hospitalizations, and secondary medical complications.

From an economic perspective, foreign mail-order pharmacies act as an informal competitive check on domestic pricing strategies. Although individual personal importation represents a small fraction of the total U.S. pharmaceutical market, it serves as a critical financial valve for vulnerable demographics. Furthermore, domestic health plans, employer purchasing coalitions, and state assistance programs closely track federal importation policy, as restrictions on foreign supply routes can alter broader efforts to lower healthcare expenditures across public and private sectors.

The debate surrounding foreign drug importation into the United States spans more than two decades, shaped by conflicting mandates between consumer affordability and regulatory oversight. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), importing prescription medications that have not received explicit FDA approval or that bypass authorized domestic distribution networks is technically illegal for individuals and non-registered commercial entities. The underlying statutory rationale rests on maintaining supply chain integrity under the Drug Supply Chain Security Act (DSCSA) to shield consumers from unverified, sub-standard, or counterfeit products.

However, recognizing the economic reality of rising prescription costs, the FDA established a formal personal importation policy within its regulatory manuals. Under this administrative guidance, border officials and FDA enforcement personnel exercise enforcement discretion. They generally allow individuals to import up to a 90-day supply of an unapproved foreign prescription drug for personal use, provided the product does not represent an unreasonable safety risk, is intended for a serious condition for which effective domestic treatment may be financially inaccessible, and is accompanied by a valid prescription from a licensed healthcare practitioner.

Legislative efforts to formalize drug importation programs culminated in Section 804 of the FD&C Act, enacted under the Prescription Drug Equity Act of 2000 and subsequently amended by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Section 804 allows the Secretary of Health and Human Services to authorize state-sponsored or commercial bulk importation of prescription drugs from Canada, provided the Secretary certifies that such importation poses no additional risk to public health and safety and results in a significant cost reduction to American consumers.

In recent years, the regulatory focus has divided into two distinct tracks: state-level commercial wholesale importation programs and direct-to-consumer mail-order imports. While several U.S. states have sought FDA approval to import select high-cost medications in bulk from Canadian wholesalers, foreign governments have taken defensive steps to protect their domestic drug supplies. Health Canada, the national public health department, implemented regulatory measures prohibiting Canadian drug distributors from exporting medications if such exports would trigger national or regional shortages in Canada. Concurrently, major U.S. pharmaceutical trade organizations have repeatedly filed administrative challenges and federal lawsuits to halt regulatory pathways that permit foreign drug importation, arguing that cross-border trade undermines safety and compromises intellectual property protections.

Reaction

The announcement of the 90-day regulatory delay is drawing focused attention from consumer rights organizations, public health advocates, pharmaceutical industry lobbies, and trade groups representing global internet pharmacies.

Patient advocacy organizations and seniors' rights groups, including nationwide consumer coalitions, typically favor policies that preserve or expand access to low-cost imported medicines. These groups argue that until domestic prescription prices are constrained through legislative reforms or direct price negotiations, international mail-order pharmacies represent an indispensable lifeline for elderly and low-income Americans. Representatives from consumer coalitions are expected to use the 90-day review period to lobby executive officials against implementing permanent restrictions.

Conversely, domestic pharmaceutical trade associations, such as the Pharmaceutical Research and Manufacturers of America (PhRMA) and biotechnology industry councils, have historically voiced strong opposition to personal and commercial drug importation. Industry representatives contend that foreign importation opens vulnerable supply channels to counterfeit, adulterated, or improperly stored pharmaceuticals. They argue that federal authorities should focus strictly on enforcing supply chain safety laws and eliminating unauthorized foreign prescription channels.

Organizations representing verified international mail-order providers, such as the Canadian International Pharmacy Association (CIPA), are expected to advocate for regulatory frameworks that distinguish licensed, credentialed foreign pharmacies from unregulated online entities. CIPA and similar bodies emphasize that their member pharmacies require valid prescriptions, maintain strict quality control standards, and source products directly from approved national supply chains.

What we don't know yet

What to watch

This report is based on original reporting published by journalist Ed Silverman.